Grifols, S.A. (GRFS)
| Market Cap | 7.82B |
| Revenue (ttm) | 6.45B |
| Net Income (ttm) | 221.57M |
| Shares Out | 855.09M |
| EPS (ttm) | 0.33 |
| PE Ratio | 50.78 |
| Forward PE | 13.28 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 206,066 |
| Open | 9.24 |
| Previous Close | 9.24 |
| Day's Range | 9.14 - 9.37 |
| 52-Week Range | 5.71 - 10.97 |
| Beta | 0.46 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 7, 2023 |
About GRFS
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihem... [Read more]
Financial Performance
In 2022, Grifols's revenue was 6.06 billion, an increase of 22.92% compared to the previous year's 4.93 billion. Earnings were 208.28 million, an increase of 10.36%.
Financial numbers in EUR Financial StatementsNews
GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564
Collaboration sets stage for GigaGen's first oncology asset to enter clinical development GIGA-564 is a differentiated anti-CTLA4 antibody with potential to enhance anti-tumor activity and mitigate im...
Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients
BARCELONA, Spain, July 20, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines, today announced that its recently con...
Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis
BARCELONA, Spain, July 18, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines, today announced it has completed enro...
Grifols Launches AlphaID™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic COPD
BARCELONA, Spain, May 11, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global leader in plasma-derived medicines and innovative diagnostic solutions, today announced it has la...
Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023
BARCELONA, Spain , April 18, 2023 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines tha...
Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye Disease
CHICAGO , March 6, 2023 /PRNewswire/ -- Selagine, Inc., a spin-out company from the University of Illinois at Chicago (UIC), announced today that it has entered into a research, development and sublic...
Grifols receives FDA clearance for AlphaID™ At Home, the first free service for U.S. consumers to determine their risk for alpha-1
AlphaID™ At Home, the company's first FDA clearance for direct-to-consumer use, enables U.S. adults to screen for their genetic risk of alpha1-antitrypsin deficiency (alpha-1) without prescription fro...
Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson
Victor Grifols Roura, who devoted 50 years to building Grifols in senior roles including CEO for 30 years, retires as non-executive Chairperson and is designated as Chairperson of Honor in recognition...
GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for High-Priority Toxins and Pathogens
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc. , a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoi...
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada
The country, with an increasing immunoglobulin (Ig) usage rate, currently imports about 85% of its Ig demand for patients in Canada who rely on this lifesaving plasma-protein therapy Building on its i...
GigaGen Publishes Research Showcasing First-Ever Clinical GMP Manufacturing and IND-Enabling Studies for its New Class of Drugs, Recombinant Polyclonal Antibodies
SOUTH SAN FRANCISCO, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint...
5 High-Performing Stocks in Historical Low PS Model Portfolio
According to model portfolio statistics, five stocks in the Historical Low Price-Sales Model Portfolio that have gained more than 6% in the year to date are Banco de Chile ( BCH , Financial), LTC Prop...
GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development
SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint ...
Grifols 2021 Annual Report on Form 20-F filed with the SEC on April 29, 2022
BARCELONA, Spain, April 29, 2022 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) announced that it has filed its 2021 Annual Report on Form 20-F with the United State...
Grifols completes the acquisition of Biotest: a strategic and transformational transaction to accelerate growth and innovation
- After obtaining all regulatory approvals, Grifols has closed the acquisition of 100% of the share capital of Tiancheng (Germany) Pharmaceutical Holdings AG, which owns 90% of the ordinary shares and...
Grifols partners with Feeding America® to help address hunger in the U.S.
BARCELONA, Spain, March 2, 2022 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a global leader in plasma-derived medicines with more than 110 years of history helping to improve the heal...
Grifols signs global collaboration and licensing agreement with Endpoint Health to develop and commercialize Antithrombin III for Sepsis
BARCELONA, Spain, Feb. 24, 2022 /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines, today announced a collaboration with E...
Grifols PharmacyKeeper ranked No. 1 as 'Best in KLAS,' extends category leadership for sixth consecutive year
BARCELONA, Spain, Feb. 9, 2022 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines and provider of technologies and services f...
Grifols acquires its first plasma donation center in Canada
BARCELONA, Spain, Jan. 4, 2022 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and one of world's top producers of plasma-derived medicines, today announced t...
Grifols reaches milestone with 300th U.S. plasma donor center, continuing to increase supply of urgently needed plasma
BARCELONA, Spain, Nov. 30, 2021 /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global leader in the development of plasma-derived therapies, today announced the opening of its 300th...
Grifols introduces ALBUTEIN FlexBag™ (Albumin [Human] U.S.P.) in 5% and 25% concentrations, a more convenient option for healthcare professionals
BARCELONA, Spain, Nov. 4, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines, today announced the launch of its latest albumin...
Grifols and Egypt inaugurate first African plasma-supply platform, in Cairo, as part of the alliance to attain self-sufficiency in plasma-derived medicines
BARCELONA, Spain, Oct. 19, 2021 /PRNewswire/ -- Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ:GRFS), one of the world's leading producers of plasma-derived medicines with a more than 110-year track record of ...
Grifols Sells Off With Effects of Pandemic
Spain-based biotech Grifols SA ( GRFS , Financial) is trading low due to the effects of the pandemic on sales and revenue. The company is completely vertically integrated in the plasma business.
Singapore's sovereign fund invests $1 billion in Grifols's U.S. unit
Singapore's wealth fund GIC agreed to invest around 1 billion dollars in Biomat, a U.S.-based plasma collection company owned by Grifols, thus becoming a strategic investor in the Spanish pharmaceutic...
Grifols introduces HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to hepatitis B
BARCELONA, Spain, June 1, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of a variety of postexposure prophyl...